RE:RE:RE:RE:Any hope?Gbathat wrote: If you review the AAIC poster, available at:
https://d1io3yog0oux5.cloudfront.net/_f444b23cf4fc6297ab91dfdf03041ca0/promisneurosciences/db/1004/8793/pdf/2023+AAIC+PMN310+poster.pdf
Figures 4 and 5 show the selectivity story.
Figure 4 is binding to target in presence of monomer (no plaque presence)
Figure 5 assesses binding to plaque, which is thought to be the driver of ARIA-E.
Drugs that bind strongly to plaque tend to have poor ARIA-E results. Acumen's ACU193 does appear to be an improvement, but not as good as PMN with respect to plaque binding.
It will be interesting to see clinical data from PRX coming out. Based on the PMN theories, it will likely be less effective due to monomer competition and cause ARIA-E due to plaque binding.
These are just my personal interpretations of the data.
My point is that PMN310 shows its selective binding to oligomers, not monomers pre-clinical still needs to be proven in humans. We're not there yet. And even if it does will it be more beneficial to fight an AD brain? Just playing with the devil's advocate.
jmo
G1945V